CPD-Accredited | FSHD: Clinical & Research Updates
November 2 @ 17:00 - 18:00 EDT
The Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC) are pleased to invite you to a webinar on Facioscapulohumeral muscular dystrophy (FSHD).
This webinar is primarily targeted at Canadian clinicians, academics, and trainees with an interest in neuromuscular disease. NMD4C and MDC are providing organisational and technical support. This is a clinical/academic webinar series supported by Sanofi-Genzyme; There is no involvement and influence from the industry on program content.
Dr. Toshifumi Yokota (chair): Development of antisense oligonucleotide-mediated therapy for the treatment of FSHD
Dr. David Uehling: The discovery of potent and selective WDR5 inhibitors as new therapeutic agents for FSHD
Dr. Hanns Lochmüller: Learnings from the ReDUX4 clinical trial in FSHD
Which outcome measures work in FSHD clinical trials
What is the landscape for FSH clinical trials in Canada
What can be done with therapeutic antisense oligonucleotides, advantages/disadvantages and differences from similar technologies
Provide an understanding of the biology and drug discovery of a small molecule WDR5 inhibitor
Provide an understanding of the therapeutic potential for WDR5 in FHSD
The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.